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Abstract
Introduction: Erectile dysfunction (ED) is common in men with systemic sclerosis (SSc) but the demographics, risk
factors and treatment coverage for ED are not well known.
Method: This study was carried out prospectively in the multinational EULAR Scleroderma Trial and Research
database by amending the electronic data-entry system with the International Index of Erectile Function-5 and
items related to ED risk factors and treatment. Centres participating in this EULAR Scleroderma Trial and Research
substudy were asked to recruit patients consecutively.
Results: Of the 130 men studied, only 23 (17.7%) had a normal International Index of Erectile Function-5 score. Thirty-
eight per cent of all participants had severe ED (International Index of Erectile Function-5 score ≤ 7). Men with ED were
significantly older than subjects without ED (54.8 years vs. 43.3 years, P < 0.001) and more frequently had simultaneous
non-SSc-related risk factors such as alcohol consumption. In 82% of SSc patients, the onset of ED was after the
manifestation of the first non-Raynaud’s symptom (median delay 4.1 years). ED was associated with severe cutaneous,
muscular or renal involvement of SSc, elevated pulmonary pressures and restrictive lung disease. ED was treated in only
27.8% of men. The most common treatment was sildenafil, whose efficacy is not established in ED of SSc patients.
Conclusions: Severe ED is a common and early problem in men with SSc. Physicians should address modifiable
risk factors actively. More research into the pathophysiology, longitudinal development, treatment and psychosocial
impact of ED is needed.
Introduction
Systemic sclerosis (SSc) is a connective tissue disorder
in which vascular alterations and endothelial damage are
prominent and lead to progressive and widespread dys-
function of various organs. Vascular symptoms such as
Raynaud’s phenomenon, digital ulcers and pulmonary
arterial hypertension are also a frequent target of diag-
nostic and therapeutic efforts [1]. Men with SSc may
develop erectile dysfunction (ED), a vascular complica-
tion that is not frequently addressed in studies. Owing
to the predominance of the female gender in SSc, stu-
dies of ED in SSc men are more difficult to perform.
The available data from small studies have suggested
that ED is more common in SSc than in the normal
population and in other autoimmune diseases [2-4]. ED
has been attributed to a vascular process with
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sum [5-8], corporeal fibrosis and accumulation of extra-
cellular matrix [5-7].
This study aims to confirm the high prevalence using
an unprecedentedly large multicentre cohort, and to
describe hitherto unaddressed SSc characteristics (auto-
antibody status, SSc subtype, disease duration) of men
with ED, to study SSc-related complications and nonre-
lated comorbidities as factors in the development of ED,
and to report on current treatment regimens.
Materials and methods
Data collection
The study was performed using the multinational data-
base of the EULAR Scleroderma Trial and Research
(EUSTAR) group, which was inaugurated in 2004. Parti-
cipating centres are required to have local ethics com-
mittee approval; patients must provide informed written
consent prior to entry into the Minimal Essential Data
S e t[ 9 ] .P a t i e n t sm u s tf u l fil the American College of
Rheumatology classification criteria for SSc. For the pur-
pose of this study, the Minimal Essential Data Set online
electronic data-entry system - which prospectively fol-
lows patients on yearly visits - was amended by a sepa-
rate data-entry page with items specific to the ED study.
EUSTAR centres intending to participate in the ED
study were displayed in this separate data-entry system
and were asked to provide all men consecutively with
the International Index of Erectile Function-5 (IIEF-5), a
self-administered questionnaire that is validated in sev-
eral languages, has high retest reliability, and has
demonstrated sensitivity and specificity for detecting
treatment-related changes [10]. The IIEF-5 provides a
numerical score that is classified into five categories:
severe ED (scores 5 to 7), moderate ED (scores 8 to 11),
mild to moderate ED (scores 12 to 16), mild ED (sores
17 to 21), and no ED (scores 22 to 25).
In addition to the IIEF-5 instrument, men were asked
to provide information about the time of ED onset and
the use of phosphodiesterase-5 inhibitors for the specific
purpose of ED treatment (not for pulmonary hyperten-
sion), as well as intraurethral or intracavernous prosta-
glandin preparations. Physicians were also questioned
about factors known to increase the risk for ED, such as
hypercholesterolaemia, diabetes mellitus, stroke, smok-
ing, peripheral macroangiopathy and coronary heart
disease.
Statistical analysis
The dataset was analysed using Stata version 11.0 (Stata-
Corp Inc., College Station, TX, USA). SSc presentations
were analysed cross-sectionally for associations between
ED and other clinical features of ED. Continuous data
were presented as the mean (± standard deviation) or
the median with interquartile range (IQR) as appropri-
ate, while binary parameters were presented as percen-
tages. Odds ratios with 95% confidence intervals and
linear regressions were calculated to estimate effect
sizes. Variables with P < 0.1 were then entered into a
multivariate logistic regression model.
Results
Participants
Twenty-two EUSTAR centres in 13 countries partici-
pated in this study, which started in October 2009.
These EUSTAR centres were prospectively following
2,469 women and 463 men (gender ratio 5.3:1). At the
time of census in May 2011, the centres had recruited a
total of 130 men for this study. A comparison between
study participants and nonparticipants demonstrates
that the participants were representative of the male
population in the EUSTAR centres with respect to
important demographic parameters and disease charac-
teristics such as age, antinuclear antibodies, and disease
duration (Table 1). Participants had a higher proportion
of puffy hands and digital ulcers, as well as a higher
modified Rodnan skin score, but less frequently an
impairment of the diffusion capacity of the lung for car-
bon monoxide below 80% of normal. Differences in sys-
tolic pulmonary arterial pressure estimated by
echocardiography were statistically significant but medi-
cally less relevant.
Prevalence of erectile dysfunction in systemic sclerosis
Of the 130 participants, only 23 men (17.7%) had a nor-
mal IIEF-5 score (≥ 22). Two men had not engaged in
any sexual activity in the 6 months prior to filling out
the IIEF-5 questionnaire and could therefore neither be
attributed to the ED group or to the non-ED group.
The remaining 105 men (81%) had variable degrees of
ED. The largest group of all participants (38%) had
severe ED (Figure 1). The median IIEF-5 score of all SSc
patients was 13 (IQR 6 to 19). Among the men with ED,
the median IIEF-5 score was 11 (IQR 5 to 16).
Comorbidities
A number of conditions are associated with ED in the
general population. These conditions include cardiovas-
cular risk factors, medications (antidepressants, seda-
tives, neuroleptics, antiepileptics, diuretics), alcoholism,
neurological and endocrine disorders, as well as pro-
static disease [8,11,12]. The majority of the participating
men had at least one such comorbidity (Table 2). Men
with ED more frequently had more than one simulta-
neous comorbidity than men with normal erections.
Traditional cardiovascular risk factors such as arterial
hypertension, diabetes mellitus, coronary heart disease,
hypercholesterolaemia and smoking were not more
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ED (13.8%) than those without ED (0%) consumed alco-
h o li ne x c e s so f2u n i t sp e rd a ya n dt w i c ea sm a n yh a d
depression (not significant). Men with severe ED (IIEF-5
scores 5 to 7) had a low prevalence of alcoholism
(5.7%), but the highest prevalence of depression as
judged by the treating physician (10.8%). Central ner-
vous system dysfunction was reported only in men with
ED, in which it consisted of stroke, multiple sclerosis
and dementia. More men with ED than those without
ED had prostatic disease, whereas endocrine or medica-
tion-related factors did not differ between both groups.
Demographics, disease characteristics and predictors of
ED
Patients with ED were significantly older than subjects
without ED (Table 3). The median SSc duration was
similar in both groups (approximately 7 years if
Table 1 Characteristics of men that were included in the ED substudy by the 22 participating centres compared to
those not included.
Nonparticipants (n = 463) Participants (n = 130) P value
Age (years) 54.3 (46.0 to 64.1) 52.3 (45.1 to 61.5) 0.12
SSc duration by Raynaud’s phenomenon (years) 6.4 (3.4 to 11.7) 7.0 (3.7 to 11.9) 0.21
SSc duration by first non-Raynaud’s symptom (years) 5.4 (2.7 to 9.2) 6.0 (3.0 to 10.3) 0.20
Topoisomerase I (Scl70)-autoantibodiespositive 42.8 46.7 0.44
Anti-centromere autoantibodies-positive 14.9 15.7 0.82
U1RNP-positive 6.5 4.7 0.51
RNA polymerase III-positive 9.4 2.8 0.08
Diffuse SSc 56.8 63.7 0.18
Puffy hands 34.3 54.6 < 0.001*
mRSS 10 (4 to 16) 13 (6 to 20) 0.01*
mRSS > 20 16.8 25.0 0.05
C-reactive protein elevation 33.6 24.5 0.07
Digital ulcers 34.7 44.0 0.04*
Synovitis 13.1 20.0 0.05
Joint contractures 33.0 31.8 0.81
Tendon friction rubs 10.2 10.0 0.94
Muscle weakness 22.2 20.9 0.76
Muscle atrophy 11.1 15.5 0.17
Creatine kinase elevation 11.6 13.3 0.58
Oesophageal symptoms 54.4 60.4 0.23
Stomach symptoms 16.0 13.5 0.50
Intestinal symptoms 18.8 12.6 0.11
Lung fibrosis on chest X-ray or HRCT 60.4 56.7 0.59
Forced vital capacity (% predicted) 89 (75 to 101) 92 (81 to 103) 0.36
Forced vital capacity < 80% 32.2 23.3 0.10
DLCO (% predicted) 66 (49 to 82) 69 (55 to 88) 0.05
DLCO < 80% 71. 59.1 0.01*
PAPsys (mmHg) 30 (25 to 37) 27 (20 to 36) 0.004*
PAPsys > 40 mmHg 22.3 19.4 0.51
Diastolic dysfunction 20.4 18.8 0.70
Pericardial effusion 7.1 5.7 0.64
Left ventricular ejection fraction < 60% 25.1 20.0 0.31
Arterial hypertension 21.5 23.6 0.75
Renal crisis 3.3 4.5 0.50
Proteinuria 8.6 9.4 0.79
EULAR SSc activity score 1.5 (0.5 to 3.0) 2 (0.5 to 3.5) 0.27
High SSc activity (score ≥ 3) 27.2 35.2 0.19
Hypocomplementaemia 5.0 5.9 0.71
Demographic parameters and disease characteristics from the EULAR Scleroderma Trial and Research database
Data presented as median (interquartile range) or percentage. DLCO; diffusion capacity of the lung for carbon monoxide; HRCT, high resolution computed
tomography; mRSS; modified Rodnan skin score; PAPsys; systolic pulmonary arterial pressure; SSc, systemic sclerosis. *Significant at P < 0.05.
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and 6 years if determined from the first non-Raynaud’s
symptom). The median duration of ED was 1.8 years
(IQR 0.3 to 4.9). Patients with more severe ED had
experienced erectile problems for a longer time (median
of 4 years in patients with IIEF-5 score ≤ 7) than those
with less severe ED. In the majority of patients, the
erectile problem started after the onset of SSc (in 90.1%
of SSc patients after the onset of Raynaud’sp h e n o m -
enon, and in 82.1% of men after the manifestation of
the first non-Raynaud’s symptom of SSc). The median
time interval from the onset of the first non-Raynaud’s
symptom of SSc to the onset of ED was 4.1 years (IQR
1.5 to 8.3 years). An analysis by ED duration revealed a
negative correlation between IIEF-5 score and time of
ED (P = 0.03). The IIEF-5 score was not correlated with
SSc duration, as measured either from the onset of Ray-
naud’s phenomenon or from the onset of first non-
Raynaud’s symptom, however, and about one-fifth of all
men have maintained normal erections many years after
SSc onset (Figure 2).
A total 52.4% of men without ED had one of the anti-
nuclear antibodies typically tested for SSc; for example,
antibodies directed against topoisomerase I (Scl70), cen-
tromere, U1 RNP and RNA polymerase III. Among men
with ED these typical antinuclear antibodies were more
prevalent (69.2%) than in men without ED (52.4%), but
the difference was not statistically significant. The preva-
lence of autoantibodies against topoisomerase I (Scl70)
was similar in the ED group and the non-ED group, but
antibodies directed against centromere, U1RNP and
RNA polymerase III were more frequent with ED (Table
3).
The presence of ED was also associated with more
severe organ involvement in SSc. Men with any form of
ED had a higher modified Rodnan skin score, and more
Figure 1 Prevalence and severity of erectile dysfunction among the 130 participants. ED, erectile dysfunction; IIEF-5, International Index of
Erectile Function-5.
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elevated pulmonary arterial pressure and restrictive lung
disease (Table 3). Men with ED also had higher EULAR
SSc activity scores than men with normal erectile func-
tion [13]. On multivariate analysis, however, only age
remained a predictor of ED (P = 0.02, R
2 = 0.42).
We also performed an analysis of organ involvement
by ED severity (Table 4). In this analysis, older age (P <
0.001) and impaired pulmonary function (P = 0.006 for
normal forced vital capacity, P =0 . 0 1f o rf o r c e dv i t a l
capacity < 80% of normal) were associated with ED
severity - indicators of pulmonary hypertension and SSc
activity.
Treatment of erectile dysfunction
Treatment information was obtained in 101 of the 105
men with ED (Table 5). A total 72.2% of men with
abnormal erections did not receive any treatment for
ED. In the remaining 27.8% of men, ED was treated
with a phosphodiesterase-5 inhibitor as the recom-
mended first-line modality in the non-SSc population.
Sildenafil was the agent most commonly used; seven of
the 15 men using sildenafil also had concomitant pul-
monary arterial hypertension. Tadalafil was used in a
total of 11 men. The proportion of patients with
tadalafil and concomitant pulmonary arterial hyperten-
sion was not captured because the study was launched
prior to the approval of tadalafil for pulmonary arterial
hypertension. Two men with moderate ED were treated
with intracavernous alprostadil injections. Three of 101
men with ED (IIEF-5 scores of 10, 16 and 20) received
combination therapy. One man was treated with sildena-
fil plus vardenafil, one man received sildenafil plus tada-
lafil and one man received sildenafil plus intracavernous
alprostadil.
Other second-line treatments for ED, such as intraure-
thral alprostadil applications or vacuum devices, were
not used. Two patients had received a penile prosthesis
for severe ED; one patient had a normal IIEF-5 score
after this procedure. The ED in the second patient who
a l s os u f f e r e df r o mm u l t i p l es c l e r o s i sh a dn o ti m p r o v e d
from the otherwise uneventful prosthesis implantation.
Discussion
Connective tissue diseases more frequently affect
women and most studies have not addressed medical
problems specific to men. This study represents the lar-
gest investigation so far of ED in men with SSc. The
prevalence of ED in our survey is similar to, or even
exceeds, the estimates from smaller studies [3,4] and is
Table 2 Comorbidities of the participants
No erectile dysfunction (n =
23)
Erectile dysfunction (n =
105)
Odds ratio (95% confidence
interval)
Cardiovascular risk factors
Systemic arterial hypertension 14.3 24.1 1.11 (0.92 to 1.34)
Diabetes mellitus 4.4 6.9 1.08 (0.82 to 1.42)
Coronary heart disease 4.4 13.3 1.17 (0.98 to 1.39)
Hypercholesterolaemia 19.1 13.3 0.92 (0.70 to 1.21)
History of smoking 31.8 42.6 1.09 (0.92 to 1.29)
Cigarette smoking (pack-years) 15 (10 to 21) 20 (9 to 30) P = 0.69
Medication
Antidepressant, sedative, neuroleptic or
antiepileptic
4.4 9.1 1.12 (0.89 to 1.40)
Thiazides or spironolactone 4.4 7.0 1.08 (0.82 to 1.43)
Alcohol consumption (> 2 units/day) 0 13.7 1.27 (1.15 to 1.40)*
Other
Depression 4.6 9.0 1.11 (0.88 to 1.39)
Central nervous system problems 0 3.9 1.23 (1.13 to 1.35)*
Prostatic disease 0 8.4 1.24 (1.13 to 1.36)*
Hormonal (hypogonadism,
hyperprolactinaemia)
0 2.8 1.23 (1.11 to 1.36)
Number of comorbidities per patient
At least one comorbidity 52.2 61.5 1.07 (0.90 to 1.28)
At least two comorbidities 13.0 36.5 1.21 (1.05 to 1.40)*
At least three comorbidities 4.4 14.4 1.17 (1.00 to 1.34)*
At least four comorbidities 0 5.8 1.23 (1.13 to 1.35)*
At least five comorbidities 0 1 1.22 (1.13 to 1.33)*
Data presented as median (interquartile range) or percentage. The star (*) denotes statistical significance.
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Page 5 of 10considerably higher than in the general population. A
study in Massachusetts, for example, calculated the pre-
v a l e n c eo fc o m p l e t ei m p o t e n c ea s5t o1 5 %i nm e n
between 40 and 70 years of age in the general popula-
tion [14]. The prevalence of ED in our study also
exceeds estimates in other chronic disease populations,
such as in diabetes mellitus (37 to 75%) [15,16], stroke
(48%) [17], and arterial hypertension (23 to 46%)
[18-20]. For rheumatoid arthritis the reported preva-
lence was 48% [4].
Patients with SSc not only have an elevated prevalence
o fE D ,t h e ya l s oh a v em o r es e v e r eE Dc o m p a r e dw i t h
the general population. The average IIEF-5 score in our
study was 13.3, which is similar to the only other study
Table 3 Comparison of participants with and without ED
No erectile dysfunction (n =
23)
Erectile dysfunction (n =
105)
Odds ratio (95% confidence
interval)
IIEF-5 score 23 (22 to 25) 11 (5 to 16) P < 0.001*
Age (years)
a 45 (35.1 to 51.8) 55.7 (47.1 to 62.9) P < 0.001*
SSc duration by Raynaud’s phenomenon (years) 7.2 (4.3 to 15.3) 7.0 (3.4 to 11.6) P = 0.44
SSc duration by first non-Raynaud’s symptom
(years)
6.6 (4.3 to 11.8) 5.6 (2.8 to 9.8) P = 0.41
Topoisomerase I (Scl70)-positive 47.6 45.1 0.98 (0.80 to 1.19)
ACA-positive 5.0 18.8 1.21 (1.02 to 1.44)*
U1RNP-positive 0 5.9 1.25 (1.12 to 1.39)*
RNA polymerase III-positive 0 3.5 1.20 (1.08 to 1.33)*
Diffuse SSc 50 65.9 1.13 (0.92 to 1.40)
Puffy hands 57.1 52.9 0.97 (0.80 to 1.16)
mRSS 7 (2 to 19) 14 (8 to 23) P = 0.05*
mRSS > 20 15.8 26.8 1.13 (0.91 to 1.40)
C-reactive protein elevation 14.3 25.3 1.13 (0.93 to 1.37)
Raynaud’s phenomenon 90.5 95.5 1.22 (0.69 to 2.17)
Digital ulcers 47.6 41.9 0.95 (0.79 to 1.16)
Synovitis 19.1 19.5 1.01 (0.80 to 1.27)
Joint contractures 19.1 33.3 1.14 (0.95 to 1.36)
Tendon friction rubs 4.8 10.3 1.13 (0.90 to 1.42)
Muscle weakness 9.5 20.7 1.15 (0.96 to 1.38)
Muscle atrophy 4.8 18.4 1.21 (1.03 to 1.42)*
Creatine kinase elevation 19.1 12.2 0.88 (0.62 to 1.25)
Oesophageal symptoms 57.1 59.1 1.02 (0.84 to 1.23)
Stomach symptoms 19.1 12.5 0.90 (0.65 to 1.23)
Intestinal symptoms 4.8 15.9 1.19 (0.99 to 1.41)
Lung fibrosis on chest X-ray or HRCT 42.9 56.9 1.13 (0.87 to 1.47)
Forced vital capacity (% predicted) 95 (87 to 107) 91 (78 to 192) P = 0.52
Forced vital capacity < 80% 9.5 25.7 1.26 (1.01 to 1.56)*
DLCO (% predicted) 81 (73 to 91) 66 (53 to 82) P = 0.08
DLCO < 80% 42.9 63.6 1.24 (0.95 to 1.61)
PAPsys (mmHg) 23.5 (0 to 28) 29 (22 to 37) P = 0.04*
PAPsys > 40 mmHg 0 24.4 1.32 (1.17 to 1.50)*
Diastolic dysfunction 15.8 17.3 1.02 (0.79 to 1.33)
Pericardial effusion 5.6 4.4 0.95 (0.53 to 1.68)
Left ventricular ejection fraction < 60% 27.8 18.3 0.88 (0.65 to 1.20)
Renal crisis 0 4.6 1.25 (1.14 to 1.38)*
Proteinuria 19.1 6.0 0.68 (0.37 to 1.22)
EULAR SSc activity score 1.0 (0.5 to 2.0) 2.5 (1.0 to 3.5) P = 0.02*
High SSc activity (score ≥ 3) 11.8 43.4 1.38 (1.09 to 1.75)*
Hypocomplementaemia 5.0 6.3 1.05 (0.72 to 1.52)
Data presented as median (interquartile range) or percentage unless indicated otherwise. DLCO, diffusion capacity of the lung for carbon monoxide; HRCT; IIEF-5,
International Index of Erectile Function-5; mRSS; modified Rodnan skin score; PAPsys, systolic pulmonary arterial pressure; SSc, systemic sclerosis.
aAge presented
as mean + standard deviation (minimum to maximum). The star (*) denotes statistical significance
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S S c[ 6 ] .I nc o m p a r i s o n ,t h ea v e r a g eI I E F - 5s c o r ei na
non-SSc population with a similar age was 21.3 [11].
About one-third of men with SSc had severe ED in our
investigation, whereas in the general population only
8.5% of the men with ED reported moderate or severe
ED [11]. In men with non-SSc causes of ED - for exam-
ple, diabetes [15,16], arterial hypertension [18-20], and
Figure 2 Severity of erectile dysfunction as a function of disease duration. Figures in bars represent the number of men within each
subgroup; y axis, cumulative percentages. ED, erectile dysfunction; SSc, systemic sclerosis.
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SSc.
Although ED manifests after SSc onset in the vast
majority of men [4], it appe a r sa sar e l a t i v e l ye a r l y
symptom of SSc with a mean delay from SSc diagnosis
of 2.7 years [4]. ED will probably not become a diagnos-
tic predictor of SSc, given the fact that ED mostly fol-
lows SSc onset. This contrasts with the role of ED in
the general population, in which ED is an important
harbinger of subsequent cardiovascular disease [8,21].
Our study confirms age as an important but nonmodi-
fiable risk factor for ED development in SSc [6]. More
importantly, our findings show an association with SSc
severity in terms of restrictive lung disease and renal
and pulmonary vasculopathy. Our study also examined
for the first time the relationship between ED and auto-
antibody status, but failed to identify a protective anti-
body or an antinuclear antibody conferring an elevated
risk of ED development. Among the modifiable risk fac-
tors of ED, the elevated alcohol consumption of men
with ED deserves attention. The present data, however,
do not permit one to differentiate whether alcohol con-
sumption is a cause of ED, is a coping strategy for ED,
or is unrelated to ED. Although the ED was more fre-
quent in SSc men than in the normal population and
age was an important risk factor for ED, the interpreta-
tion of the SSc effect in our study would be facilitated
by the recruitment of a non-SSc control group matched
for known ED risk factors.
Treatment guidelines for ED in the general population
suggest that modifiable risk factors such as lifestyle, psy-
chological or drug-related factors be minimised prior to
or in conjunction with specific ED therapy [12,22]. In
our study, about one-fifth of SSc patients had at least
one such modifiable comorbidity. A higher proportion
of men with SSc-related ED than those without ED had
more than two comorbidities, indicating that these fac-
tors may contribute to the development of ED not only
in the general population but also in patients with SSc
and that these factors should be aggressively addressed.
In the non-SSc population, pharmacotherapy with phos-
phodiesterase-5 inhibitors is recommended as first-line
specific treatment [22]. In SSc, the efficacy data of phos-
phodiesterase-5 inhibitors for ED with on-demand silde-
nafil were disappointing [23], whereas the longer-acting
tadalafil is slightly better evaluated [24,25]. Second-line
Table 4 Organ involvement by severity of erectile dysfunction
Erectile dysfunction severity
Mild (n = 25) Mild to moderate (n = 26) Moderate (n = 14) Severe (n = 40) P value
IIEF-5 score 19 (18 to 20) 14 (13 to 16) 10 (8 to 11) 5 (5 to 6) < 0.001*
Age (years) 50.5 (45.3 to 61.0) 54.1 (47.1 to 63.9) 54.9 (48.6 to 62.0) 57.3 (48.8 to 64.0) < 0.001*
Duration of erectile dysfunction (years) 1.0 (0.6 to 2.3) 1.2 (0.1 to 2.6) 2.8 (0.1 to 5.0) 4.0 (1.0 to 6.4) 0.08
Diffuse SSc 59.1 47.6 72.7 82.1 0.08
C-reactive protein elevation 9.1 18.2 41.7 37.4 0.06
Forced vital capacity (% predicted) 99 (86 to 108) 100 (91 to 108) 84 (78 to 90) 81 (66 to 98) 0.006*
Forced vital capacity < 80% 16.7 6.3 33.3 47.6 0.01*
DLCO (% predicted) 70 (53 to 81) 79 (61 to 90) 64 (49 to 69) 56 (45 to 74.5) 0.02*
PAPsys (mmHg) 32 (25 to 38) 25 (21 to 29) 27 (19 to 36) 35 (25 to 39) 0.006*
PAPsys > 40 mmHg 25 10.0 16.7 38.5 0.02*
EULAR SSc activity score 1.5 (0.5 to 3.0) 2.5 (1.0 to 4.5) 3.5 (3.0 to 5.5) 2 (0.5 to 3.5) 0.047*
High SSc activity (score > 3) 26.7 47.1 83.3 40.0 0.02*
Data presented as median (interquartile range) or percentage. DLCO, diffusion capacity of the lung for carbon monoxide; IIEF-5, International Index of Erectile
Function-5; PAPsys, systolic pulmonary arterial pressure; SSc, systemic sclerosis. *Significant at P < 0.05.
Table 5 Treatment of erectile dysfunction
Erectile dysfunction severity
Mild (n = 25) Mild to moderate (n = 26) Moderate (n = 14) Severe (n = 40) All (n = 105)
Sildenafil 20 8 31 11 15
Tadalafil 12 8 15 11 11
Vardenafil 0 4 0 0 1
Alprostadil urethral 0 0 0 0 0
Alprostadil cavernous 0 0 15 0 2
Vacuum device 0 0 0 0 0
Penile prosthesis 0 0 0 5 2
Data represent percent of men on each treatment modality. A total of 3 men received combination therapy.
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or intracavernous or intraurethral applications of alpros-
tadil were used by only a minority of men with SSc, and
a similar minority was equipped with a penile prosthesis
although successful implantations were previously
reported [7].
Our study has both strengths and limitations. It repre-
sents the largest analysis of impotence in men with SSc.
The multicentric nature of our investigations may, on
the one hand, be more representative of all men affected
by the disease than a monocentric study, but on the
other hand may lead to difficulties in standardising data
collection. Although centres were asked to recruit men
consecutively, there is always a risk of recruitment bias,
as indicated by the slight differences observed between
participants and non-participants. Depression was only
judged by the treating physician and not captured with
a validated questionnaire. Lastly, it would have been
interesting to correlate the prevalence of ED with
changes on nailfold capillaroscopy but these data were
not available in the majority of patients.
Conclusion
Our study indicates that ED is a common, severe and
early problem in men with SSc. ED is associated with a
higher age of patients and the presence of restrictive
lung disease, as well as with renal and pulmonary vascu-
lopathy. The reasons for the overall low treatment cov-
erage were not the assessed in this study but clearly a
heightened awareness among physicians and more
research into pathophysiology, longitudinal develop-
ment, treatment and psychosocial impact are urgently
needed.
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